FTSE 100 news / Companies and sectors / Haleon / 19 October 2026

Haleon (HLN): news on Monday 19 October 2026

+7.0 strongly positive

Coverage focused on Haleon's results helped by Sensodyne and oral health strength, ahead of a Q3 update. A Goldman Sachs Buy rating and a new headache remedy launch added to the generally positive tone.

What drove it

Sensodyne-led results
Goldman Sachs Buy rating
Excedrin headache remedy launch

The 5 stories

Each headline's own score, strongest first. Links go to the publisher.

+9.2 Blue-Chip Stock Haleon (LSE:HLN) Results Powered By Sensodyne: What It Means Kalkine Media
Results driven by Sensodyne strength, framed positively.
+8.7 FTSE 100 Haleon (LSE:HLN): Oral Health Strength Lifts Profit Ahead of Q3 Update Kalkine Media
Oral health strength lifts profit ahead of Q3 update.
+7.5 Goldman Sachs keeps Buy rating for Haleon stock at GBp 460.00 - ad-hoc-news.de ad-hoc-news.de
Goldman Sachs maintains Buy rating with 460p target.
+4.2 Will Headache Remedy Launch Change Haleon's (LSE:HLN) Narrative Yahoo Finance
Headache remedy launch could shift narrative; mildly positive, uncertain.
+2.0 Weekly Recap: Excedrin digital-pet campaign and Deep Malde appointment TradingView
Excedrin campaign and appointment; mostly routine marketing and personnel news.

Haleon: every day · Pharma and healthcare on 19 October 2026 · FTSE 100 overview for the day